This WIREs title offers downloadable PowerPoint presentations of figures for non-profit,
educational use, provided the content is not modified and full credit is given to the author
References1 Singal, R, Ginder, GD. DNA methylation. Blood 1999, 93: 4059–4070. 2 Duncan, BK, Miller, JH. Mutagenic deamination of cytosine residues in DNA. Nature 1980, 287: 560–561. 3 Fazzari, MJ, Greally, JM. Epigenomics: beyond CpG islands. Nat Rev Genet 2004, 5: 446–455. 4 Cross, SH, Bird, AP. CpG islands and genes. Curr Opin Genet Dev 1995, 5: 309–314. 5 Li, E, Bestor, TH, Jaenisch, R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 1992, 69: 915–926. 6 Shukla, V, Vaissiere, T, Herceg, Z. Histone acetylation and chromatin signature in stem cell identity and cancer. Mutat Res 2008, 637: 1–15. 7 van Holde, K. Chromatin. New York: Springer‐Verlag; 1989. 8 Malik, HS, Henikoff, S. Phylogenomics of the nucleosome. Nat Struct Biol 2003, 10: 882–891. 9 Jenuwein, T, Allis, CD. Translating the histone code. Science 2001, 293: 1074–1080. 10 Strahl, BD, Allis, CD. The language of covalent histone modifications. Nature 2000, 403: 41–45. 11 Kouzarides, T. Histone methylation in transcriptional control. Curr Opin Genet Dev 2002, 12: 198–209. 12 Zhang, Y, Reinberg, D. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev 2001, 15: 2343–2360. 13 Fischle, W, Wang, Y, Allis, CD. Histone and chromatin cross‐talk. Curr Opin Cell Biol 2003, 15: 172–183. 14 Shukla, A, Chaurasia, P, Bhaumik, SR. Histone methylation and ubiquitination with their cross‐talk and roles in gene expression and stability. Cell Mol Life Sci 2008, 66: 1419–1433. 15 Guenther, MG, Levine, SS, Boyer, LA, Jaenisch, R, Young, RA. A chromatin landmark and transcription initiation at most promoters in human cells. Cell 2007, 130: 77–88. 16 Ooi, SK, Qiu, C, Bernstein, E, et al. DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature 2007, 448: 714–717. 17 Cedar, H, Bergman, Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 2009, 10: 295–304. 18 Eden, S, Hashimshony, T, Keshet, I, Cedar, H, Thorne, AW. DNA methylation models histone acetylation. Nature 1998, 394: 842. 19 Nan, X, Campoy, FJ, Bird, A. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 1997, 88: 471–481. 20 Ballestar, E, Paz, MF, Valle, L, et al. Methyl‐CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J 2003, 22: 6335–6345. 21 Schlesinger, Y, Straussman, R, Keshet, I, et al. Polycomb‐mediated methylation on Lys27 of histone H3 pre‐marks genes for de novo methylation in cancer. Nat Genet 2007, 39: 232–236. 22 Jones, PA, Baylin, SB. The epigenomics of cancer. Cell 2007, 128: 683–692. 23 He, L, Hannon, GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004, 5: 522–531. 24 Rouhi, A, Mager, DL, Humphries, RK, Kuchenbauer, F. MiRNAs, epigenetics, and cancer. Mamm Genome 2008, 19: 517–525. 25 Hwang, HW, Mendell, JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer 2006, 94: 776–780. 26 Bartel, DP. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136: 215–233. 27 Calin, GA, Dumitru, CD, Shimizu, M, et al. Frequent deletions and down‐regulation of micro‐ RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002, 99: 15524–15529. 28 Calin, GA, Sevignani, C, Dumitru, CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004, 101: 2999–3004. 29 Croce, CM, Calin, GA. miRNAs, cancer, and stem cell division. Cell 2005, 122: 6–7. 30 Lujambio, A, Ropero, S, Ballestar, E, et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 2007, 67: 1424–1429. 31 Lu, J, Getz, G, Miska, EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435: 834–838. 32 Katayama, S, Tomaru, Y, Kasukawa, T, et al. Antisense transcription in the mammalian transcriptome. Science 2005, 309: 1564–1566. 33 Yu, W, Gius, D, Onyango, P, et al. Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. Nature 2008, 451: 202–206. 34 Tufarelli, C, Stanley, JA, Garrick, D, et al. Transcription of antisense RNA leading to gene silencing and methylation as a novel cause of human genetic disease. Nat Genet 2003, 34: 157–165. 35 Espada, J, Ballestar, E, Fraga, MF, et al. Human DNA methyltransferase 1 is required for maintenance of the histone H3 modification pattern. J Biol Chem 2004, 279: 37175–37184. 36 Feinberg, AP, Vogelstein, B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983, 301: 89–92. 37 Warnecke, PM, Bestor, TH. Cytosine methylation and human cancer. Curr Opin Oncol 2000, 12: 68–73. 38 Feinberg, AP, Tycko, B. The history of cancer epigenetics. Nat Rev Cancer 2004, 4: 143–153. 39 Ng, MH, Wong, IH, Lo, KW. DNA methylation changes and multiple myeloma. Leuk Lymphoma 1999, 34: 463–472. 40 Eden, A, Gaudet, F, Waghmare, A, Jaenisch, R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003, 300: 455. 41 Bestor, TH. Transposons reanimated in mice. Cell 2005, 122: 322–325. 42 Esteller, M. Epigenetics in cancer. N Engl J Med 2008, 358: 1148–1159. 43 Lohrum, M, Stunnenberg, HG, Logie, C. The new frontier in cancer research: deciphering cancer epigenetics. Int J Biochem Cell Biol 2007, 39: 1450–1461. 44 Greger, V, Passarge, E, Hopping, W, Messmer, E, Horsthemke, B. Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Hum Genet 1989, 83: 155–158. 45 Kastrinakis, NG, Gorgoulis, VG, Foukas, PG, Dimopoulos, MA, Kittas, C. Molecular aspects of multiple myeloma. Ann Oncol 2000, 11: 1217–1228. 46 Alexander, DD, Mink, PJ, Adami, HO, et al. Multiple myeloma: a review of the epidemiologic literature. Int J Cancer 2007, 120( Suppl. 12): 40–61. 47 Seidl, S, Ackermann, J, Kaufmann, H, et al. DNA‐methylation analysis identifies the E‐cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies. Cancer 2004, 100: 2598–2606. 48 Chim, CS, Fung, TK, Liang, R. Disruption of INK4/CDK/Rb cell cycle pathway by gene hypermethylation in multiple myeloma and MGUS. Leukemia 2003, 17: 2533–2535. 49 Chim, CS, Kwong, YL, Fung, TK, Liang, R. Methylation profiling in multiple myeloma. Leuk Res 2004, 28: 379–385. 50 Uchida, T, Kinoshita, T, Ohno, T, Ohashi, H, Nagai, H, et al. Hypermethylation of p16INK4A gene promoter during the progression of plasma cell dyscrasia. Leukemia 2001, 15: 157–165. 51 Guillerm, G, Depil, S, Wolowiec, D, Quesnel, B. Different prognostic values of p15(INK4b) and p16(INK4a) gene methylations in multiple myeloma. Haematologica 2003, 88: 476–478. 52 Guillerm, G, Gyan, E, Wolowiec, D, et al. p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. Blood 2001, 98: 244–246. 53 Galm, O, Wilop, S, Reichelt, J, et al. DNA methylation changes in multiple myeloma. Leukemia 2004, 18: 1687–1692. 54 Chiusolo, P, Farina, G, Putzulu, R, et al. Analysis of MTHFR polymorphisms and P16 methylation and their correlation with clinical‐biological features of multiple myeloma. Ann Hematol 2006, 85: 474–477. 55 Gonzalez‐Paz, N, Chng, WJ, McClure, RF, et al. Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood 2007, 109: 1228–1232. 56 Ribas, C, Colleoni, GW, Felix, RS, et al. p16 gene methylation lacks correlation with angiogenesis and prognosis in multiple myeloma. Cancer Lett 2005, 222: 247–254. 57 Mateos, MV, Garcia‐Sanz, R, Lopez‐Perez, R, et al. Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. Br J Haematol 2002, 118: 1034–1040. 58 Dib, A, Barlogie, B, Shaughnessy, JD, Kuehl, WM, Jr. Methylation and expression of the p16INK4A tumor suppressor gene in multiple myeloma. Blood 2007, 109: 1337–1338. 59 Chim, CS, Liang, R, Leung, MH, Kwong, YL. Aberrant gene methylation implicated in the progression of monoclonal gammopathy of undetermined significance to multiple myeloma. J Clin Pathol 2007, 60: 104–106. 60 Deligezer, U, Erten, N, Akisik, EE, Dalay, N. Methylation of the INK4A/ARF locus in blood mononuclear cells. Ann Hematol 2006, 85: 102–107. 61 Lavelle, D, DeSimone, J, Hankewych, M, Kousnetzova, T, Chen, YH. Decitabine induces cell cycle arrest at the G1 phase via p21(WAF1) and the G2/M phase via the p38 MAP kinase pathway. Leuk Res 2003, 27: 999–1007. 62 Ng, MH, To, KW, Lo, KW, et al. Frequent death‐associated protein kinase promoter hypermethylation in multiple myeloma. Clin Cancer Res 2001, 7: 1724–1729. 63 Chim, CS, Liang, R, Fung, TK, Choi, CL, Kwong, YL. Epigenetic dysregulation of the death‐associated protein kinase/p14/HDM2/p53/Apaf‐1 apoptosis pathway in multiple myeloma. J Clin Pathol 2007, 60: 664–669. 64 Chim, CS, Fung, TK, Cheung, WC, Liang, R, Kwong, YL. SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood 2004, 103: 4630–4635. 65 Galm, O, Yoshikawa, H, Esteller, M, Osieka, R, Herman, JG. SOCS‐1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood 2003, 101: 2784–2788. 66 Depil, S, Saudemont, A, Quesnel, B. SOCS‐1 gene methylation is frequent but does not appear to have prognostic value in patients with multiple myeloma. Leukemia 2003, 17: 1678–1679. 67 Reddy, J, Shivapurkar, N, Takahashi, T, et al. Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors. Oncogene 2005, 24: 732–736. 68 Chim, CS, Liang, R, Fung, TK, Kwong, YL. Infrequent epigenetic dysregulation of CIP/KIP family of cyclin‐dependent kinase inhibitors in multiple myeloma. Leukemia 2005, 19: 2352–2355. 69 Song, YF, Xu, R, Zhang, XH, et al. High‐frequency promoter hypermethylation of the deleted in liver cancer‐1 gene in multiple myeloma. J Clin Pathol 2006, 59: 947–951. 70 Hurt, EM, Thomas, SB, Peng, B, Farrar, WL. Reversal of p53 epigenetic silencing in multiple myeloma permits apoptosis by a p53 activator. Cancer Biol Ther 2006, 5: 1154–1160. 71 Takada, S, Morita, K, Hayashi, K, et al. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with multiple myeloma. Eur J Haematol 2005, 75: 505–510. 72 Tatetsu, H, Ueno, S, Hata, H, et al. Down‐regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth. Cancer Res 2007, 67: 5328–5336. 73 Turner, JG, Gump, JL, Zhang, C, et al. ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood 2006, 108: 3881–3889. 74 Murai, M, Toyota, M, Satoh, A. et al. Aberrant DNA methylation associated with silencing BNIP3 gene expression in haematopoietic tumours. Br J Cancer 2005, 92: 1165–1172. 75 Wang, Z, Zhang, Y, Ramsahoye, B, Bowen, D, Lim, SH. Sp17 gene expression in myeloma cells is regulated by promoter methylation. Br J Cancer 2004, 91: 1597–1603. 76 Wang, Z, Zhang, J, Zhang, Y, Lim, SH. SPAN‐Xb expression in myeloma cells is dependent on promoter hypomethylation and can be upregulated pharmacologically. Int J Cancer 2006, 118: 1436–1444. 77 Peng, B, Hodge, DR, Thomas, SB, et al. Epigenetic silencing of the human nucleotide excision repair gene, hHR23B, in interleukin‐6‐responsive multiple myeloma KAS‐6/1 cells. J Biol Chem 2005, 280: 4182–4187. 78 Peng, B, Hurt, EM, Hodge, DR, Thomas, SB, Farrar, WL. DNA hypermethylation and partial gene silencing of human thymine‐ DNA glycosylase in multiple myeloma cell lines. Epigenetics 2006, 1: 138–145. 79 Martin, P, Santon, A, Garcia‐Cosio, M, Bellas, C. hMLH1 and MGMT inactivation as a mechanism of tumorigenesis in monoclonal gammopathies. Mod Pathol 2006, 19: 914–921. 80 Chim, CS, Pang, R, Fung, TK, Choi, CL, Liang, R. Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma. Leukemia 2007, 21: 2527–2536. 81 Hodge, DR, Peng, B, Pompeia, C, et al. Epigenetic silencing of manganese superoxide dismutase (SOD‐2) in KAS 6/1 human multiple myeloma cells increases cell proliferation. Cancer Biol Ther 2005, 4: 585–592. 82 Drucker, L, Tohami, T, Tartakover‐Matalon, S, et al. Promoter hypermethylation of tetraspanin members contributes to their silencing in myeloma cell lines. Carcinogenesis 2006, 27: 197–204. 83 Houde, C, Li, Y, Song, L, et al. Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines. Blood 2004, 104: 3697–3704. 84 Bacolla, A, Pradhan, S, Larson, JE, Roberts, RJ, Wells, RD. Recombinant human DNA (cytosine‐5) methyltransferase. III. Allosteric control, reaction order, and influence of plasmid topology and triplet repeat length on methylation of the fragile X CGG.CCG sequence. J Biol Chem 2001, 276: 18605–18613. 85 Okano, M, Bell, DW, Haber, DA, Li, E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999, 99: 247–257. 86 Hodge, DR, Peng, B, Cherry, JC, et al. Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation. Cancer Res 2005, 65: 4673–4682. 87 Kiziltepe, T, Hideshima, T, Catley, L, et al. 5‐Azacytidine, a DNA methyltransferase inhibitor, induces ATR‐mediated DNA double‐strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Mol Cancer Ther 2007, 6: 1718–1727. 88 Heller, G, Schmidt, WM, Ziegler, B, et al. Genome‐wide transcriptional response to 5‐aza‐2′‐deoxycytidine and trichostatin a in multiple myeloma cells. Cancer Res 2008, 68: 44–54. 89 Issa, JP, Garcia‐Manero, G, Giles, FJ, et al. Phase 1 study of low‐dose prolonged exposure schedules of the hypomethylating agent 5‐aza‐2′‐deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004, 103: 1635–1640. 90 Figueroa, ME, Reimers, M, Thompson, RF, et al. An integrative genomic and epigenomic approach for the study of transcriptional regulation. PLoS One 2008, 3: e1882. 91 Figueroa, ME, Skrabanek, L, Li, Y, et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 2009, 114: 3448–3458. 92 Pompeia, C, Hodge, DR, Plass, C, et al. Microarray analysis of epigenetic silencing of gene expression in the KAS‐6/1 multiple myeloma cell line. Cancer Res 2004, 64: 3465–3473. 93 Hodges, E, Smith, AD, Kendall, J, et al. High definition profiling of mammalian DNA methylation by array capture and single molecule bisulfite sequencing. Genome Res 2009, 19: 1593–1605. 94 Weber, M, Davies, JJ, Wittig, D et al. Chromosome‐wide and promoter‐specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet 2005, 37: 853–862. 95 Irizarry, RA, Ladd‐Acosta, C, Carvalho, B, et al. Comprehensive high‐throughput arrays for relative methylation (CHARM). Genome Res 2008, 18: 780–790. 96 Khulan, B, Thompson, RF, Ye, K, et al. Comparative isoschizomer profiling of cytosine methylation: the HELP assay. Genome Res 2006, 16: 1046–1055. 97 Figueroa, ME, Wouters, BJ, Skrabanek, L, et al. Genome‐wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T‐lymphoid features. Blood 2009, 113: 2795–2804. 98 Ball, MP, Li, JB, Gao, Y, et al. Targeted and genome‐scale strategies reveal gene‐body methylation signatures in human cells. Nat Biotechnol 2009, 27: 361–368. 99 Sohal, D, Yeatts, A, Ye, K, et al. Meta‐analysis of microarray studies reveals a novel hematopoietic progenitor cell signature and demonstrates feasibility of inter‐platform data integration. PLoS One 2008, 3: e2965.